

Taspoglutide

Phase III study results to date



Study	Description	Headline Results/status
emerge 1	Monotherapy	Primary endpoint met: superior HbA1c reduction versus placebo
emerge 2	H2H vs. Byetta	Primary endpoint met: significant <u>superiority</u> on HbA1c versus twice-daily exenatide
emerge 3	pioglitazone + metformin	Data in 2010
emerge 4	H2H vs. Januvia vs. placebo	Primary endpoint met: <u>superiority</u> in HbA1c reduction versus sitagliptin
emerge 5	H2H vs. Lantus (37 units)	Primary endpoint met: <u>non-inferiority</u> in HbA1c change versus insulin glargine
emerge 6	SU ± metformin	Data in 2010
emerge 7	Obese T2DM patients	Primary endpoint met: HbA1c superiority versus placebo in patients with high BMI
emerge 8	History of CV events	Recruitment started Jan 2010

29

Taspoglutide pre-filled syringe vs. Liraglutide and Byetta LAR delivery systems



Taspoglutide PFS*



Liraglutide FlexPen



Byetta LAR**

Device	Single-use, staked-in-needle	Multiple Use	Single-use, syringe & vial
Needle	29 gauge	32 gauge	23 gauge
Steps	1. remove cap 2. inject 3. discard	1. attach needle 2. prime pen 3. set dose 4. inject 6. discard needle	1. re-constitute 2. draw into syringe 3. inject dose 4. discard
Admin	Weekly	Daily	Weekly

*Pre-filled syringe **Long-acting release

30